2009-10-20 17:55:02 -
London, October , 20, 2009
Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
Dr. Wolfgang A. Renner, CEO of Cytos Biotechnology Ltd will attend
and meet investors at the South Europe & Switzerland Midcap Event on
Thursday, October 22, 2009 in Paris, France.
Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a
new class of biopharmaceutical products - the Immunodrugs(TM).
Immunodrugs(TM) are intended for use in the treatment and prevention
of common chronic diseases, which afflict millions of people
worldwide. Immunodrugs(TM) are designed to instruct the patient's
immune system to produce desired therapeutic antibody or T cell
responses that modulate chronic disease processes. Taking advantage
of the high flexibility of its Immunodrug(TM) platform, Cytos
Biotechnology has built a diversified pipeline of Immunodrug(TM)
candidates in various disease areas, of which six are currently in
clinical development. The Immunodrug(TM) candidates are developed
both in-house and together with Novartis, Pfizer and Pfizer Animal
Health. Founded in 1995 as a spinoff from the Swiss Federal Institute
of Technology (ETH) in Zurich, the Company is located in Schlieren
(Zurich). Currently, the Company has 86 full-time employees. Cytos
Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).
For further information please contact:
Patricia Koch
Corporate Communications
Assistant Executive Board
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: patricia.koch@cytos.com
Website: www.cytos.com
--- End of Message ---
Cytos Biotechnology AG
Wagistrasse 25 Zurich-Schlieren Switzerland
WKN: 804352; ISIN: CH0011025217; Index: SPIEX, SPI, Swiss All Share
Index;
Listed: Main Market in SIX Swiss Exchange;
